Curebase, k'hamphani e ikemiselitseng ho etsa demokrasi ho fihlella lithuto tsa bongaka, 'me Blue Note Therapeutics, k'hamphani e fanang ka lengolo la ngaka ea digital therapeutics (PDT) e ikemiselitseng ho fokotsa moroalo oa mofetše le ho ntlafatsa liphetho, e phatlalalitse tšebelisano 'moho tekong ea bongaka e tla ithuta katleho. ea mekhoa e 'meli ea phekolo ea digital. Litlhare ka bobeli tsa dijithale ho lebelletsoe ho ba le tšusumetso bophelong ba kelello le ba 'mele ha li sebelisoa hammoho le mefuta e mengata ea tlhokomelo ea oncology.
Sepheo sa teko e kopaneng le Curebase ke ho holisa boiteko ba rona ba ho hira bakuli ba nang le khatello ea maikutlo e amanang le mofetše le ba ka ruang molemo tekong e felletseng, ho kenyeletsoa le ba sebetsanang le maemo a lapeng ba sa khoneng kapa ba sa batleng ho ea tekong. sebaka. Sena se tla nolofalletsa Blue Note ho fihlella palo ea bakuli ba neng ba sa emeloa hanyane lithutong tsa setso tse thehiloeng sebakeng sa marang-rang. Batho ba nang le mofetše le ba nang le thahasello tekong ena ea sebele ba ka ithuta ho eketsehileng mona.
Sethala sa Curebase's decentralized clinical trial (DCT) se tla sebelisoa ho thaotha bankakarolo, ho lekola, tumello, le ho ba thusa ho ba tataisa tlalehong le mesebetsing e hlokehang bakeng sa phuputso. Curebase e tla sebelisa ts'ebetso ea eona e pharalletseng ea sebaka sa marang-rang le taolo ea boithuto ho etsa boithuto. Blue Note e hira bakuli ba 353 bakeng sa teko e hole ka botlalo, e tla qala mathoasong a Hlakubele. Lintlha tse tsoang tekong ena li lebelletsoe ho ts'ehetsa litlatsetso tsa nako e tlang tsa taolo ea Blue Note Therapeutics ho Tsamaiso ea Lijo le Lithethefatsi ea US.
“Bakuli ba tšoeroeng ke kankere hangata ba ba le khatello ea maikutlo, matšoenyeho le khatello ea maikutlo. Ho ba bangata, matšoao ana a eketsehile nakong ea seoa sa COVID-19 ka lithibelo tsa tlhokomelo ea bophelo bo botle le tšitiso ea tlhokomelo ea mofetše, "ho boletse Geoffrey Eich, CEO, Blue Note Therapeutics. "Tšebelisano ea rona le Curebase ea thabisa kaha e kopanya bokhoni ba rona bo ikhethang ba ho holisa phihlello ea rona ea ho hira batho bakeng sa teko ena e ncha, e felletseng ea bongaka. Ka ho sebelisa theknoloji ea morao-rao ea thekenoloji, joale re khona ho fa bakuli tsela e bonolo ea ho nka karolo le seo re tšepang hore se tla ntlafala 'meleng le kelellong."
Moetso oa DCT oa Curebase o netefatsa lithuto tse fapaneng hobane ho ka kenyelletsoa palo ea batho ba ikhethileng - bao hangata ba haelloang haholo litekong tsa bongaka - ba ka kenyelletsoa. Liwebsaete tsa lipatlisiso tsa k'hamphani li boetse li fa lingaka likhetho tse ncha le tse ikhethang tsa ho fa bakuli ba bona, ho sa tsotelehe hore na ba hokae.
Tom Lemberg, CEO le mothehi oa Curebase o itse: "Batho ba fumanoeng ba e-na le mofetše ha ba sebetsane le lefu lena 'meleng feela, empa hangata ba loana le khatello ea maikutlo le menahano e mebe. "Re ts'epa hore teko ena e tla bonts'a hore batho ba nang le mofetše ba ka imoloha khatellong ea bona ea maikutlo ka har'a boiketlo le boiketlo ba malapa a bona."
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- Curebase, a company committed to democratizing access to clinical studies, and Blue Note Therapeutics, a prescription digital therapeutics (PDT) company dedicated to easing the burden of cancer and improving outcomes, have announced a collaboration on a virtual clinical trial that will study the effectiveness of two digital therapeutics.
- The goal of the joint trial with Curebase is to maximize our recruitment efforts with patients experiencing cancer-related distress and who may benefit from a fully virtual trial, including home-based subjects who can’t or wouldn’t want to travel to a trial site.
- Using the latest in digital technology, we’re now able to offer patients a convenient way to participate and what we hope will be improved physical and mental health.
